Publications by authors named "S Heltai"

Claim this Profile
L
Loss of CYLD promotes splenic marginal zone lymphoma.
Athanasios Pseftogas, Jessica Bordini, Silvia Heltai, Ferdinando Bonfiglio, Georgios Gavriilidis

Hemasphere· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL.
A Campanella, A Capasso, S Heltai, C Taccetti, E Albi

Am J Hematol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimal residual disease-driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLL.
Lydia Scarfò, Silvia Heltai, Elisa Albi, Eloise Scarano, Luana Schiattone

Blood· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relevance of Minimal Residual Disease in the Era of Targeted Agents.
Silvia Heltai, Paolo Ghia, Lydia Scarfò

Cancer J· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The IL-1/IL-1 receptor axis and tumor cell released inflammasome adaptor ASC are key regulators of TSLP secretion by cancer associated fibroblasts in pancreatic cancer.
Emanuela Brunetto, Lucia De Monte, Gianpaolo Balzano, Barbara Camisa, Vincenzo Laino, Silvia Heltai

J Immunother Cancer· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis